Furthermore, since bFGF and VEGF promote angiogenesis by contributing to tumor growth and spread, they have been widely associated with shorter overall survival in non-small cell lung cancer patients [46], as well as in subjects affected by hepatocellular carcinoma and non-Hodgkin lymphoma [47,48]. Here, FGF2 is linked to non-small cell lung carcinoma.